Mufemilast

ArtNr	HY-145583-1ea
Hersteller	MedChem Express
CAS-Nr.	1255909-03-5
Menge	1 ea
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 1 mg 25 mg 50 mg 5 mg
Kategorie	Inhibitors & Compound Libraries Small Molecules
Typ	Molecules
Specific against	other
Purity	99.67
Citations	[1]Liu Tian, et al., Efficacy and Safety of Mufemilast in Patients with Behçet's Syndrome: A Phase 2, Double-Blind, Placebo-Controlled Trial. \|[2]Yilmaz, O., et al., (2024). New and emerging oral therapies for psoriasis. Drugs in context, 13, 2024-5-6.\|[3]Peng, T., et al., (2020). Advances in the Development of Phosphodiesterase-4 Inhibitors. Journal of medicinal chemistry, 63(19), 10594–10617.\|[4]Liu, X., et al., (2018). Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC-MS/MS and its application to a PK study. Bioanalysis, 10(11), 863–875. \|[5]Liu, X., et al., (2018). Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC-MS/MS and its application to a PK study. Bioanalysis, 10(11), 863–875.
Smiles	O=C1C2=C(NC(C)=O)SC=C2C(N1[C@@H](C3=CC(OCC)=C(C=C3)OC)CS(C)(=O)=O)=O
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	Hemay005
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Metabolism-protein/nucleotide metabolism
Manufacturer - Targets	Phosphodiesterase (PDE)
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	466.53
Product Description	Mufemilast (Heymay005) is a selective and orally active phosphodiesterase 4 (PDE4) inhibitor (IC50 = 80-120 nM). Mufemilast modulates cytokines upregulated in Behςet’s syndrome (BS). Mufemilast displays a significant inhibitory effect on TNF-α, which is an important proinflammatory cytokine target in the disease process of psoriasis. Mufemilast can be studied in research for diseases such as rheumatoid arthritis, psoriasis and BS[1][2][3][4][5].
Manufacturer - Research Area	Inflammation/Immunology; Others
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Metabolic Enzyme/Protease
Isoform	PDE4
Clinical information	Phase 3

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-145583-1ea-safety-datasheet.pdf